RPRX
Royalty Pharma Plc
NASDAQ · Healthcare · Biotechnology · US
$67.30
−0.40%Next report
Analyst consensus
- Next report date
- Feb 10, 2027
- EPS estimate
- $1.52
- Revenue estimate
- $960.7M
Latest reported
- Last report date
- Nov 4, 2026
- EPS actual
- $1.21
- EPS estimate
- $1.18
- Revenue actual
- $890.0M
- Revenue estimate
- $884.8M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 0
- EPS in line (12Q)
- 3
- Avg surprise (4Q)
- +5.7%
- Revenue beats (12Q)
- 3
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $71
- PT range
- $67 – $78
- Analysts
- 4
4 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 4, 2026 | $1.18 | $1.21 | Beat 2.54% | $890.0M |
| Aug 5, 2026 | $1.27 | $1.32 | Beat 3.94% | $773.0M |
| May 6, 2026 | $1.22 | $1.30 | Beat 6.56% | $925.0M |
| Feb 11, 2026 | $1.33 | $1.46 | Beat 9.77% | $622.0M |
| Nov 5, 2025 | $0.99 | $1.17 | Beat 17.71% | $609.3M |
| Aug 6, 2025 | $1.03 | $1.14 | Beat 10.68% | $578.7M |
| May 8, 2025 | $0.95 | $1.06 | Beat 11.23% | $568.2M |
| Aug 8, 2024 | $0.96 | $0.96 | Miss -0.52% | $537.3M |
| May 9, 2024 | $0.99 | $0.98 | Miss -0.71% | $568.0M |
| Feb 15, 2024 | $1.01 | $1.15 | Beat 13.86% | $596.0M |
| Feb 15, 2023 | $1.56 | $1.56 | In line | $565.7M |
| Aug 4, 2022 | $0.78 | $0.79 | Beat 1.28% | $536.0M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 10, 2027